NM_032043.3:c.3374_3376delCAG
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 1P and 0B. PM4_Supporting
The NM_032043.3(BRIP1):c.3374_3376delCAG(p.Ala1125del) variant causes a disruptive inframe deletion change. The variant allele was found at a frequency of 0.0000235 in 1,613,598 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_032043.3 disruptive_inframe_deletion
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152242Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000559 AC: 14AN: 250592Hom.: 0 AF XY: 0.0000516 AC XY: 7AN XY: 135574
GnomAD4 exome AF: 0.0000246 AC: 36AN: 1461238Hom.: 0 AF XY: 0.0000248 AC XY: 18AN XY: 726930
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152360Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74520
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:3
The c.3374_3376delCAG variant (also known as p.A1125del) is located in coding exon 19 of the BRIP1 gene. This variant results from an in-frame CAG deletion at nucleotide positions 3374 to 3376. This results in the in-frame deletion of an alanine at codon 1125. This variant was also observed in 1/3251 individuals who met eligibility criteria for hereditary breast and ovarian cancer syndrome (Lerner-Ellis J et al. J Cancer Res Clin Oncol, 2021 Mar;147:871-879) but was only present in control individuals in another breast cancer case-control study (Easton DF et al. J Med Genet, 2016 05;53:298-309). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be neutral by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This variant causes an in-frame deletion of 1 amino acid of the BRIP1 protein. To our knowledge, functional studies have not been performed for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 14/250592 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
c.3374_3376del, located in exon 20 of the BRIP1 gene, consists in the deletion of 3 nucleotides, predicted to cause an in-frame deletion of 1 amino acid p.(Ala1125del).This variant is found in 14/267468 alleles at a frequency of 0.005% in the gnomAD v2.1.1 database, non-cancer dataset. The SpliceAI algorithm predicts no significant impact on splicing . To our knowledge, neither relevant clinical data nor well-established functional studies have been reported for this variant. It has been reported in a breast cancer-affected patient (PMID:32885271). It has also been reported in 2 out of 5242 controls and none of 13,213 breast cancer patients (PMID: 26921362). This variant has been reported in the ClinVar database (7x uncertain significance) and has not been reported in LOVD. Based on currently available information, the variant c.3374_3376del should be considered an uncertain significance variant, according to ACMG/AMP classification guidelines. -
not specified Uncertain:1
- -
Breast and/or ovarian cancer Uncertain:1
- -
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Uncertain:1
This variant, c.3374_3376del, results in the deletion of 1 amino acid(s) of the BRIP1 protein (p.Ala1125del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs745344948, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with BRIP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 188402). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not provided Uncertain:1
In-frame deletion of 1 amino acid in a non-repeat region; In silico analysis supports a deleterious effect on protein structure/function; Observed in individuals with a personal and family history of breast and/or ovarian cancer, as well as in unaffected control groups (PMID: 32885271, 26921362); This variant is associated with the following publications: (PMID: 32885271, 26921362) -
Malignant tumor of breast Uncertain:1
The BRIP1 p.Ala1125del variant was not identified in the literature. The variant was identified in dbSNP (ID: rs745344948) as "With Uncertain significance allele” and ClinVar (classified as uncertain significance by Invitae and GeneDx). The variant was identified in control databases in 14 of 245568 chromosomes at a frequency of 0.00006 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the European population in 14 of 111430 chromosomes (freq: 0.0001), while the variant was not observed in the African, Ashkenazi Jewish, East Asian, Finnish, Latino, Other, or South Asian populations. This variant is an in-frame deletion resulting in the removal of Alanine (Ala) residue at codon 1125; the impact of this alteration on BRIP1 protein function is not known. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -
BRIP1-related disorder Other:1
Variant interpreted as Uncertain significance and reported on 06-09-2018 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at